Effect of N-acetylcysteine treatment on brain glutamate concentrations in nicotine dependence: A double-blind placebo controlled study.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON24054

Enrollment

Registered

2012-08-14

Start date

2012-06-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nicotine dependence

Interventions

14 day administration of n-acetylcysteine (2400mg/d). The control group will receive a placebo.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Men; 2. 25-55 years old; 3. Smoking at least 15 cigarettes a day.

Exclusion criteria

Exclusion criteria: 1. Major illnesses; 2. Dependent on any other substance other than nicotine; 3. Currently on medication; 4. Ulcers; 5. Color blind.

Design outcomes

Primary

Measure	Time frame
1. Glutamate concentrations in dACC and striatum; 2. Self-reported craving; 3. Self-reported withdrawal symptoms; 4. Neurocognitive tasks.	—

Contacts

Public ContactMieke Mors-Schulte, ter

Academic Medical Center University of Amsterdam Department of Psychiatry PA3-225 P.O. box 22660

m.termors.schulte@gmail.com+31 (0)20 8913704

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)